November 1, 2025 – The Indian government has issued a global call to pharmaceutical companies and research institutions to accelerate the development of a vaccine and therapeutics for the Nipah virus, following recent outbreaks and heightened concerns over its potential for widespread transmission.

The initiative, led by the Indian Council of Medical Research (ICMR) in collaboration with the Ministry of Health and Family Welfare, invites expressions of interest from domestic and international biotech firms. Proposals must focus on vaccine candidates, monoclonal antibodies, and antiviral treatments capable of addressing the deadly henipavirus, which has a fatality rate of up to 75% in some outbreaks.

"Nipah remains a priority pathogen with epidemic potential," said Dr. Rajiv Bahl, Director-General of ICMR, in a statement. "We are seeking innovative partnerships to translate promising research into deployable solutions, ensuring India is prepared for future threats."

The move comes amid ongoing sporadic cases in Kerala, where the virus has claimed lives in recent years, most notably during the 2018 and 2021 outbreaks. India has reported over 20 confirmed cases since 2001, with fruit bats identified as the primary natural reservoir. The World Health Organization (WHO) lists Nipah among its blueprint priority diseases due to its zoonotic origins and lack of approved vaccines or specific treatments.

Eligible firms are required to submit detailed development plans, including preclinical and clinical trial data, by December 15, 2025. The government has pledged funding support, regulatory fast-tracking, and access to biosafety level-4 facilities for selected partners. ICMR emphasized collaborations with entities experienced in viral hemorrhagic fevers, such as those involved in Ebola or COVID-19 vaccine efforts.

Global players like Moderna, Bharat Biotech, and Serum Institute of India have previously explored Nipah candidates, with some in early-stage trials. The new tender aims to build on these efforts, potentially leveraging mRNA technology or recombinant platforms.

Health experts warn that climate change and urbanisation could increase human-bat interactions, elevating Nipah risks in South Asia. "Proactive investment in countermeasures is critical," added a WHO spokesperson.

The ICMR tender is available on its official portal, with evaluations slated for early 2026. This step underscores India's push toward self-reliance in pandemic preparedness under the 'Atmanirbhar Bharat' initiative.